Skip to content
Screener

Treasury Stock at other companies

Viatris logo
ViatrisVTRS
$1.16B+35.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$10.98M0.0%

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.78B+0.8%
Enterprise value$1.72B-7.6%
P/E16.4×
P/S1.8×-0.5×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemJune 30,2026December 31,2025
Common Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 202533
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025(53,817)(33,249)
Additional paid-in capital620,249596,036
Retained earnings (Accumulated deficit)31,104(23,099)
Accumulated other comprehensive (loss) income, net of tax(327)1,033
Total Stockholders’ Equity597,212540,724

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's treasury stock?
ANI Pharmaceuticals (ANIP) reported treasury stock of $53.82M in Q2 2026.
How has ANI Pharmaceuticals's treasury stock changed year-over-year?
ANI Pharmaceuticals's treasury stock increased by 70.3% year-over-year, from $31.59M to $53.82M.
What is the long-term trend for ANI Pharmaceuticals's treasury stock?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's treasury stock has grown at a 71.4% compound annual growth rate (CAGR), from $2.25M to $33.25M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about ANI Pharmaceuticals's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude